5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 18.104.22.168) - Pipeline Review, H1 2019
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 22.214.171.124) pipeline Target constitutes close to 22 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The latest report 5' Nucleotidase - Pipeline Review, H1 2019, outlays comprehensive information on the 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 126.96.36.199) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 188.8.131.52) - 5′-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5'nucleotides. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 3, 1, 6 and 6 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Ovarian Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Metastatic Breast Cancer, Pancreatic Cancer, Bladder Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Fallopian Tube Cancer, Gastric Cancer, Kidney Cancer (Renal Cell Cancer), Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Muscle Invasive Bladder Cancer (MIBC), Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Peritoneal Cancer, Renal Cell Carcinoma, Sarcomas and Uterine Cancer.
Furthermore, this report also reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 184.108.40.206) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Reasons to buy
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook